Tremfya®

Understanding Tremfya® 

Tremfya® (guselkumab) is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23), a cytokine involved in inflammatory processes. It is approved for the treatment of adults with moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active ulcerative colitis.

How Tremfya® Works:

• IL-23 Inhibition: Guselkumab binds to the p19 subunit of IL-23, preventing its interaction with the IL-23 receptor. This inhibition reduces the release of pro-inflammatory cytokines and chemokines, thereby decreasing inflammation associated with certain autoimmune conditions.

• Administration: Tremfya® is administered via subcutaneous injection. The recommended dosing schedule for plaque psoriasis and psoriatic arthritis is 100 mg at weeks 0 and 4, followed by 100 mg every 8 weeks thereafter. For ulcerative colitis, the dosing regimen may vary; consult the prescribing information for detailed guidance.

FDA Approval:

• July 13, 2017: Approved for the treatment of moderate to severe plaque psoriasis in adults.

• July 2020: Expanded approval to include treatment of active psoriatic arthritis in adults.

• September 11, 2024: Further expanded approval for the treatment of moderately to severely active ulcerative colitis in adults.

For more information, please visit the Tremfya® patient website and speak with your healthcare provider to determine if Tremfya® is the right treatment option for you.